Valeritas — Investor Presentation (August 2018)
31 slides from Valeritas's investor presentation, Aug 20, 2018
Slide 1: Valeritas Corporate Presentation August 2018
Valeritas Corporate Presentation NASDAQ: VLRX August 2018 Improving health and simplifying life for people with diabetes ©2018 Valeritas, Inc.
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation shall not be deemed an offer to sell securities nor a solicitation of an offer to purchase securities. Any sale by the company shall be made pursuant to a definitive purchase agreement. Unless otherwise stated in this presentation, references to “Valerita
Slide 3: Rapidly Ramping Revenue & Poised for Significant Value Creation
Valeritas: Rapidly Ramping Revenue & Poised for Significant Value Creation Turnaround Significant Market Selling Model Validated, Attractive Financial Profile, Complete Opportunity Revenue Growth Accelerating Limited Additional Financing Company and its Global Type 2 diabetes New high-touch sa
Slide 4: Type 2 Diabetes Overview: V-Go $1.6B U.S. Opportunity
Type 2 Diabetes Overview: V-Go® $1.6B U.S. Opportunity U.S. Diabetes Market Overview1 Key Type 2 Market Data Points ~23 million diagnosed people with diabetes . 5.6 million U.S. Type 2 patients on insulin 2 ~7 million (90%-95% Type 2) Insulin Users . 80% of Type 2 patients on insulin are not achievi
Slide 5: Current Insulin Delivery Standard of Care Highly Dissatisfying for Type 2 Insulin Users
Current Insulin Delivery Standard of Care for Type 2 Highly Dissatisfying Type 2 Insulin Users Intentionally Skip and/or Current Insulin Delivery Standard of Care Forget to Take Injections1 Most Type 2 patients will not inject away from home2 “Drugs don’t work in people who don’t take them.” -C. Eve
Slide 6: The V-Go Solution Designed for Patients with Type 2 Diabetes
The V-Go® Solution Designed for Patients with Type 2 Diabetes V-Go’s Benefits Discreet, Low Profile Simple to Use Convenient Cost Neutral Better A1c Control* Self-contained Sharps Container Pharmacy vs. DME * Company data, kff.org (11 published clinical papers and 48 presentations at National Confer
Slide 7: V-Go Competition: Pens not Pumps
V-Go® Competition: Pens not Pumps Unique Needs of Type 2 Patients Creates Valeritas’ Opportunity & Differentiates it from Others TYPE 1 TYPE 2 Typical Patient Engaged / Advocate Embarrassment / Stigma Attitude Complex Device More Likely Less Likely Acceptable? (~30% of Type 1 are on pump therapy)1 W
Slide 8: Strong Clinical Evidence
Strong Clinical Evidence Demonstrated Statistically Published Significant Improvements in A1c1-10 12 Clinical Papers Improved Diabetes Management V-Go Patients Performance Measures4,7,9,10 >1K Studied Lowered Total Daily Dose of Insulin Presentations at National (Prescribed / Administered)1-10 56 Co
Slide 9: V-Go: Improved A1c Control with Less Insulin
V-Go®: Improved A1c Control with Less Insulin A Prospective Study of 415 Patients Showed V-Go Superiority vs. Standard Treatment Optimization (STO)1 Greater Improvement in A1c2 Less Insulin Used & More Cost Effective V-Go STO n=169 n=246 29% Less Insulin with V-Go vs STO at 4 months (54 vs 72 u/day)
Slide 10: New Higher-Service Sales and Marketing Model
New Higher-Service Sales and Marketing Model DIRECT SALES REPs EDUCATION PROMOTION ON-LINE ADs INDIRECT REPs DEMO KIT KOLs DESIRE PRESCRIBE TARGETED PATIENT PHYSICIAN PRINT ADs CONFERENCES • Activate patients to seek and ask for V-Go® • Target high insulin volume prescribers • Direct-to-Patient mult
Slide 11: U.S. Direct Sales Footprint
U.S. Direct Sales Footprint Significant Opportunity for Sustained Robust Growth via Disciplined Sales Force Expansion . ~50 Direct Reps . Disciplined addition of reps over time to achieve national coverage ©2018 Valeritas, Inc. 11
Slide 12: Accelerating 20%+ Revenue Growth
Accelerating 20%+ Revenue Growth $7,000 Sequential Quarterly Revenue Key Observations (in 000’s) (Q1 2016-Q2 2018) . Q1 ‘16 revamped sales & marketing model $6,500 • Direct reps reduced from 64 to 28 in Jan ‘16 $6,000 • Focused high-touch and higher-service sales & marketing model adopted . $5,500 Q
Slide 13: Our Goal: 15% Share in Addressable U.S. Markets
13 Our Goal: 15% Share in Addressable U.S. Markets 15% Share of Type 2 Patients in U.S. (Already on Insulin but not at Goal) can Generate ~$1.6B Revenue Addressable U.S. Type 2 Target Share Annual U.S. Revenue Patient Population 2M Multiple 1 Daily Injections $700M With 15% Market Share 4.5M Insulin
Slide 14: International Markets – Significant Market Opportunity
International Markets – Significant Market Opportunity Global Diabetes Stats1 International Distribution Agreements . Currently 425 million suffer diabetes; expected to be . Recent international distribution 629 million by 2045 (~90% Type 2) agreements signed with premier regional distributors . Aug
Slide 15: Robust Pipeline of New V-Go Products
Robust Pipeline of New V-Go Products V-Go Line Extension Products Under development Provide Path to the Broader Diabetes & Insulin Market V-Go® V-Go® SIMTM V-Go® Prefill1,3 1,2 • Flagship product commercially available (Simple Insulin Management) Being developed to: • Filled by patient by transferri
Slide 16: Strategy for Sustained Growth & Expansion
Strategy for Sustained Growth & Expansion + Grow Our Share Expand Our Reach Leverage Pipeline • Expand # of targets per rep • V-Go accessory • ~50 direct sales reps TM • Expand U.S. field presence V-Go® SIM with blue tooth • Targeting ~1,200 prescribers (accounts) connectivity • Drive V-Go® share in
Slide 17: Stronger Device Margin Mitigates Future Capital Needed to Break-Even
Stronger Device Margin Mitigates Future Capital Needed to Break-Even Quarterly Revenue Level at Which 45% Gross Valeritas Projected Gross Margins * $70 ($ in million) Margin was Achieved 50% GM in Q4 2018 at $60 $61.1 $7M to $8M Revenue $50 $40 . High margin at low revenue $30 . $27.0 Profitability
Slide 18: Financial Summary
Financial Summary Financial Summary Quarterly Summary YTD Summary ($ in millions) 2Q18 2Q17 Change 2018 2017 Change Revenue $6.5 $4.8 +36% $12.6 $9.4 +34% Gross Profit $3.1 $1.8 +71.5% $6.0 $3.5 +69.4% Gross Margin 47.6% 37.7% +990 bp 47.6% 37.6% +1000 bp Net Loss $11.0 $12.0 -7.5% $22.7 $23.8 -4.6%
Slide 19: Rapidly Ramping Revenue & Poised for Significant Value Creation
Valeritas: Rapidly Ramping Revenue & Poised for Significant Value Creation Turnaround Significant Market Selling Model Validated, Attractive Financial Profile, Complete Opportunity Revenue Growth Accelerating Limited Additional Financing Company and its Global Type 2 diabetes New high-touch sa
Slide 20: Valeritas Appendix August 2018
Valeritas Corporate Presentation Appendix NASDAQ: VLRX August 2018 ©2018 Valeritas, Inc.. 20
Slide 21: 4.5M U.S. Type 2 Patients on Insulin are not Achieving A1c Goal
4.5M U.S. Type 2 Patients on Insulin are not Achieving A1c Goal Despite Serious Health Consequences % of Type 2 Patients on Insulin NOT at Goal1 Impact of Improving A1c Control2 Every 1% improvement in A1c decreases diabetes related events in: AT A1c Goal NOT AT A1c Goal 20% 80% Deaths Heart Attacks
Slide 22: Significant Market Opportunity for Valeritas in the U.S.
Significant Market Opportunity for Valeritas in the U.S. U.S. Type 2 Diabetes Initial V-Go® Target Market V-Go® Potential Revenue 5.6M Patients with Type 2 2M Type 2 on Multiple Daily Injections Diabetes On Insulin1 With Current Sales Force 15% “IF” Market Share V-G0® Revenue 2 2M on 15% $75 Million
Slide 23: Robust Clinical Data
Robust Clinical Data Validated Ability of V-Go® to Deliver Clinically Relevant Reductions in A1c with Less Insulin V-GoAL1 SIMPLE2 VALIDATE 13 EVIDENT4 IMPROVE5 JONES6 KAISER7 UMASS8 MOTIV9 ENABLE10 Baseline 9.9% 8.8% 9.6% 9.7% 9.8% 9.1% 9.8% 10.7% 8.7% 9.2% N=169 N=87 N=204 N=84 N= 103 N=69 N=60 N=
Slide 24: Simple Titration Approach Significantly Lowered A1c
Simple Titration Approach Significantly Lowered A1c Use of a weekly physician-driven mealtime dosing titration approach with patients with Type 2 Diabetes uncontrolled on prior regimens A1c (%) Insulin Dose (Units) 8.7 144 A1c Goal Achievement Before V-Go® On V-Go < 7% 13% 47% 7.1* < 8% 60* 40% 87%
Slide 25: Less Insulin Needed and Lower A1c vs. Multiple Injections
Less Insulin Needed and Lower A1c vs. Multiple Injections Switching from Prior Multiple Daily Injections to V-Go® Results in Significant Reductions in Insulin and A1c VALIDATE evaluated patients switched to V-Go when Glycemic Control was Suboptimal on Prior Regimens Prescribed On V-Go 117 Patient 10
Slide 26: Clinical Benefit Realized with V-Go
Clinical Benefit Realized with V-Go® Switching Patients from Prior Insulin Injections to V-Go Resulted in Improved A1c and Less Insulin Regardless of Baseline Insulin Regimen or Dose All Patients Switched to V-Go1 Patients with High Dose MDI Switched to V-Go2 (MDI Patients Prescribed between 90- 300
Slide 27: Patients Who Utilize V-Go Like How it Fits into Their Lifestyle
Patients Who Utilize V-Go® Like How it Fits into Their Lifestyle >90% of Patients are satisfied with the ability of V-Go to fit with their Lifestyle Extremely Satisfied = 39% Very Satisfied= 32% Satisfied= 16% Somewhat Satisfied= 7% Not Satisfied=6% N=720 patients prescribed V-Go dLife Survey 1Q 201
Slide 28: Scalable Business Model to Drive Shareholder Value
Scalable Business Model to Drive Shareholder Value Launch V-Go® Prefill Expand Product Advance Sales Force Launch V-Go Next in U.S. V-Go SIMTM Gen / Line Collaborate (Int’l) Extensions Launch with h-Patch Expand V-Go® SIMTM Technology Increase Sales Force (U.S.) Continue to Share in U.S. prudently i
Slide 29: V-Go with V-Go SIM Technology
V-Go® with V-Go SIMTM Technology Simple Insulin Management™ MANAGEMENT APPLICATIONS PATIENT PHYSICIAN INDUSTRY PAYERS V-Go SIM sends data one-way to a V-Go SIM will enable simple and Adherence, utilization and other Evidence of treatment smart device. SIM App provides data timely access to data that
Slide 30: V-Go: Easy to Use & High Quality Commercial Scale Manufacturing
V-Go®: Easy to Use & High Quality Commercial Scale Manufacturing V-Go Device Overview V-Go® EZ FILL Basal rate is 24 hour Basal rate begins spring-driven with the push of a button Basal rate flow restrictor Needle • Simple filling does not require calculations, On-demand bolus measuring or needles f
Slide 31: Experienced and Proven Executive Management Team
Experienced and Proven Executive Management Team Geoffrey Jenkins EVP Manufacturing Joseph Saldanha Operations, R&D Chief Business Officer John Timberlake President & CEO, Board Member Matt Nguyen ErickLucera Chief Commercial Officer Chief Financial Officer ©2018 Valeritas, Inc. 31
Valeritas Holdings — Investor Presentation (August 2018) on 6ix